Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year.

Cardiometabolic disorders company Gemphire Therapeutics

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE